Business
Appointment of Martin Reeves as SVP
Appointment of Martin Reeves as SVP.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \nRNS Number : 9112Y Oxford BioDynamics PLC 09 March 2017 \n\n9 March 2017\n \nOxford BioDynamics Plc\n(\"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \nOxford BioDynamics announces appointment of Martin Reeves as Senior Vice President of Commercial Development\n \nOxford BioDynamics Plc (AIM: OBD), a revenue-generating biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry, announces that Martin Reeves has been appointed as Senior Vice President of Commercial Development. Martin will be based in the US and will take up this role in March 2017.\n \nMartin has over 20 years' experience in business development and strategic planning, including Teva Pharmaceuticals where he was Head of Business Development for Global Branded Products. He was previously Vice President of Business Development and Strategic Planning at Cephalon where, in his fourteen years at the company, he played a key role in defining the strategic direction for growth and diversification globally, including planning strategies to enter into new markets such as Asia. Cephalon was bought by Teva in 2011 for $6.8 billion.\n \nPrior to joining Cephalon, Martin held project management roles at Wyeth-Ayerst and Smith Kline Beecham. Martin started his career as a Research Biochemist at Smith Kline & French and holds a degree in Biochemistry from London University.\n\nChristian Hoyer Millar, CEO of Oxford BioDynamics said:\n \n\"We are delighted that Martin will be joining the Company as Senior Vice President of Commercial Development. His considerable experience in business development within the sector will be a great asset to Oxford BioDynamics as we look to leverage IP licensing opportunities with our award-winning, proprietary technology platform, EpiSwitch™.\"\n \nFor further details contact:\n \nOxford BioDynamics Plc  ...